Clinical Trials for Breast Cancer

A Phase I Dose Escalation and Dose Expansion Study of AND019 in Patients With Estrogen Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Advanced or Metastatic Breast Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls postmenopausal women with advanced or metastatic ER-positive, HER2-negative breast cancer who have progressed on prior endocrine therapy and no more than one chemotherapy for advanced disease, to receive oral AND019, an investigational selective estrogen receptor degrader (SERD) targeting the estrogen receptor. The study focuses on evaluating the safety and early activity of AND019 as monotherapy.

ClinicalTrials.gov ID: NCT05187832

Ph 1/1b/2 Multicenter, Open-Label, FIH Dose Esc & Dose Exp Study to Assess Safety and Tolerability of Orally Administered PMD-026 as a Single Agent and in Combination in Patients With Metastatic or Locally Advanced (Inoperable) RSK2+ Breast Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with RSK2-positive, HR+/HER2- locally advanced or metastatic breast cancer who have progressed after CDK4/6 inhibitor plus endocrine therapy, testing the investigational oral RSK inhibitor PMD-026 (which targets all four RSK isoforms in the MAPK/PDK-1 pathway) as monotherapy and in combination with fulvestrant. Eligible patients must provide tumor tissue for RSK2 analysis and have measurable disease.

ClinicalTrials.gov ID: NCT04115306

A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors that are refractory to, have progressed after, or are intolerant to standard therapies may receive oral AMXI-5001, a novel dual PARP1/2 and microtubule polymerization inhibitor, as monotherapy in this open-label study. Participants must have ECOG 0-1 and measurable or evaluable disease; no concurrent cancer therapy or strong CYP3A4 modulators are allowed.

ClinicalTrials.gov ID: NCT04503265

In Situ Vaccination With Flt3L, Radiation, and Poly-ICLC Combined With Pembrolizumab in Patients With Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, and Head and Neck Squamous Cell Carcinoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with indolent non-Hodgkin’s lymphoma (excluding aggressive subtypes), metastatic breast cancer, or head and neck squamous cell carcinoma who have peripherally accessible tumors, and tests intratumoral Flt3L (dendritic cell growth factor) and poly-ICLC (TLR3 agonist) plus low-dose local radiation combined with systemic pembrolizumab (PD-1 inhibitor). Patients may have had prior PD-1/PD-L1 therapy, and the regimen aims to enhance local and systemic anti-tumor immune responses.

ClinicalTrials.gov ID: NCT03789097